Summary Cytotoxic drug resistance developing after chemotherapy is thought to be the main cause of treatment failure in several human tumours, including small cell lung cancer (SCLC). Cell lines showing drug resistapce following prolonged exposure to a single agent frequently acquire resistance to several functionally unrelated drugs, the phenomenon of multi-drug resistance (MDR). Classical MDR is thought to arise from changes effecting a reduction in intracellular availability of cytotoxic drugs. We describe a flow cytometry (FCM) technique to monitor the MDR phenotype in drug resistant variants of SCLC and non-SCLC cell lines. The technique is based on a multiparametric analysis of the nuclear binding of a model chemotherapeutic agent, the fluorescent dye Hoechst 33342 (Ho342), which is capable of supra-vital staining of DNA in intact, viable cells. A laboratory derived drug resistant SCLC cell line, H69/LX4, showed a significant (30%) reduction in nuclear binding compared to the parental line H69/P. Exposure to verapamil (VPL) rapidly increased (within 2min) nuclear binding of Ho342, and the new equilibrium of nuclear staining, attained within 20 min, remained lower than the level achieved in the parental cell line, suggesting some ability of H69/ LX4 to limit the effect of the drug efflux blocker. A drug resistant large cell carcinoma line showed only a small reduction (10%) in nuclear binding when compared to the parent line, and this difference was not altered by VPL. A drug resistant adenocarcinoma line showed less than 10% difference in nuclear binding compared with the parental line and neither line was significantly affected by VPL treatment. Our findings suggest that different mechanisms of resistance may occur in lung tumours of different tissue types. This technique may be extended to the rapid and direct examination of biopsy specimens of human solid tumours for evidence of multi-drug resistance.
Emergence of resistance to initially effective cytotoxic drugs is a major cause of treatment failure in small cell lung cancer, a disease characterised by high initial response rates to chemotherapy but ultimately low incidence of long term control. Frequently post-chemotherapy relapse is refractory even to cytotoxic drugs to which the tumour has not previously been exposed. In vitro models of drug resistance have provided much information on the cellular pathways which may be involved. Postulated mechanisms include: reduced drug accumulation (Skovsgaard & Nissen, 1982; Inaba et al., 1979) , altered intracellular distribution of drug (Supino et al., 1986) , reduced DNA cleavage (Glisson et al., 1986; Capranico et al., 1986; Supino et al., 1988) or altered drug activity at other target sites (Potmesil et al., 1988) . The development of 'classical' multi-drug resistance (classical MDR) is a frequent outcome after selection of resistance in vitro, such a phenotype is thought to reflect the increased efflux of cytotoxic drugs by an energy-dependent transport mechanism involving membrane located P-glycoprotein (Ling et al., 1974) , a finding which has been confirmed in several (Riordan & Ling, 1985) , but not all (Slovak et al., 1988; Mirski et al; , cell lines showing MDR.
The analysis of patterns of drug uptake is clearly fundamental to the study of chemo-responsiveness of tumour populations, yet whole population extraction methods cannot identify important differences in intracellular location of the drug and are inappropriate where there is possible cellular heterogeneity. This paper considers the use of multiparameter flow cytometry (FCM) to evaluate the MDR phenotype in tumour cell populations, using a technique to detect anomalies in nuclear accumulation of a model chemotherapeutic agent, Hoechst dye 33342 (Ho342). Ho342 is a vital, DNA-specific, bis-benzimidazole dye, which shows considerable fluorescence enhancement upon binding noncovalently to the minor groove of the double helix, permitting the flow cytometric determination of dye uptake and subsequent interaction with a defined intracellular target. The uptake of this agent has been shown to parallel that of a number of cytotoxic drugs involved in MDR and to correlate with cellular sensitivity to these drugs (Lalande et al., 1981) ; it is also modified by those agents that are known Correspondence: S.A. Morgan. Received 13 January 1989, and in revised form, 5 April 1989. to partially overcome the MDR phenotype (calmodulin inhibitors and Ca2+ channel blockers; Krishan, 1987) .
The Ho342-DNA fluorescence emission spectrum is known to show a shift to longer wavelengths as the dye: DNAphosphate ratio increases (Smith et al., 1985) , reflecting a reduction in binding energy that occurs at higher concentrations of DNA-bound dye due to co-operativity between ligand molecules. We have used the shift in fluorescence .-emission spectrum which occurs at early time points after H°342 treatment in the analysis of (i) changes in the intracellular availability of this model cytotoxic agent in human SCLC and non-SCLC lung cancer cell lines, and (ii) the responsiveness of drug resistant cells to verapamil (VPL).
Materials and methods
Cell lines and culture conditions Stock cultures of human cell lines were maintained in RPMI medium supplemented with 10% fetal calf serum, penicillin and streptomycin (all Gibco Europe Ltd), at 37°C in an 8% Co2/92% air mixture. The origins and characteristics of the cell lines are shown in Table I . NCI-H69/P (H69/P) and H69/LX4 (LX4) grew as free-floating aggregates; COR-L23, MOR and their drug resistant variants grew as adherent monolayers. The procedure for the derivation of drug resistant cell lines in this laboratory, by step-wise exposure to increasing adriamycin (ADM) concentrations, has been reported previously (Twentyman et al., 1986b Cell suspensions were analyzed directly after fluorochrome treatment using a flow cytometer, details of which have been published previously (Watson, 1981) , incorporating a high light collection efficiency flow chamber (Watson, 1985 
Results
The DNA content and cell cycle distribution of asynchronously growing parent and resistant lines of both SCLC and adenocarcinoma types were similar (Table I ). The large cell carcinoma line COR-L23 showed a greater G2/M proportion and COR-L23R a greater G1 DNA content than H69/P, so that the mean cellular DNA content of these lines was, respectively, 1.5 and 1.8 times that of H69/P. As the level of H°342 fluorescence is dependent on cellular DNA contentas well as the intranuclear fluorochrome content -the fluorescence values shown are corrected for the mean cellular DNA content of the whole cell population with respect to H69/P.
The increase in nuclear fluorescence of H69/P and LX4 cells as a function of exposure period to Ho342 is shown in Figure 1 . The drug resistant cell line showed a slower 
aFigures in brackets indicate resistance factor to Adriamycin (Twentyman et al., 1986b) development of fluorescence at all wavelengths (only 400 nm and 600 nm are shown) which was most pronounced at longer wavelengths (50% reduction at 600 nm compared with 10% at 400 nm). By considering the ratio of two fluorescence values the influence of cellular DNA content on total fluorescence is removed and different cell lines can be directly compared on the basis of the rate at which ligand is binding to DNA (i.e. the spectral shift). This change in fluorescence spectrum, due to altered cellular content of the dye, is demonstrated by considering the ratio of the 600 nm value to that at 400 nm (Figure 2 ). After Ho342 treatment of H69/P, a spectral shift occurred during the initial 20min time interval, due to increasing dye-DNA binding, whereas the drug resistant line LX4 showed no alteration of the fluorescence ratio during this period, reflecting a significant limitation on the intracellular availability of the ligand for interaction with DNA. It was noted that a small proportion of cells in all preparations showed instantaneous (<1 min) development of fluorescence at both wavelengths simultaneously. These cells are considered to be non-viable because they are unable to provide any barrier to Ho342-DNA binding and simulta-
neously show efficient staining with propidium iodide (data not shown). The effect of even small numbers of these nonviable cells was both to increase the whole population fluorescence and to increase the apparent ratio of the 600 nm/400 nm fluorescence emission, particularly at early time intervals after fluorochrome treatment. This significantly alters the fluorescence ratio of the drug resistant line LX4 because of the relatively low levels of absolute fluorescence, and would result in an overestimate of drug uptake (e.g. the 2min time points in Figure 1) . In all subsequent analyses presented here cells showing instantaneous spectral shift patterns after Ho342 treatment have been excluded by dual parameter analysis as indicated in the Materials and methods.
A 30min pretreatment of LX4 cells with VPL resulted in increased Ho342-DNA fluorescence at all wavelengths on subsequent fluorochrome treatment (see Figure 3) , from 30 to 50% that of the H69/P control, indicating increased intracellular availability of the fluorochrome; no significant change was observed with H69/P given this treatment. The time course of the effect of VPL on LX4 was clearly demonstrated by adding VPL after 25min prior exposure to fluorochrome, at which time both sensitive and ADMresistant lines had reached an equilibrium for Ho342-DNA fluorescence (Figure 4 ). Under these conditions the VPLinduced increase in fluorescence of LX4 occurred at a rate as rapid as the initial phase of H°342 uptake by H69/P. The observed increase in the fluorescence ratio of LX4 reached a new equilibrium value below that of the parent cell line within 20 minutes of Ho342 addition, after which there was no further change despite continued exposure to both VPL and dye ( Figure 5) ; clearly the treatment did not fully reverse the phenotype of reduced intracellular availability of Ho342.
Further experiments demonstrated the fluorescence shift to be VPL concentration dependent, but at higher concentrations abnormalities in the forward scatter characteristic, and reduction in cell number that also occurred, suggested that VPL was having toxic effects (results not shown).
We have attempted to demonstrate a similar mechanism of reduced Ho342-DNA binding in drug resistant non-SCLC lines COR-L23-R and MOR-R compared to the parent lines, from which they had been derived by intermittent ADM exposure in an identical manner to LX4. Both were found to show much smaller differences in Ho3,2 DNA fluorescence between the parent and corresponding drug resistant lines.
COR/L23 cells (large cell carcinoma; Figure 6a ) showed a plateau fluorescence value which was only slightly greater than COR/L23-R (7% at 400nm and 2% at 600nm); MOR Ho342 incubation period (min) cells (adeno-carcinoma; Figure 6b ) showed approximately 10% greater fluorescence (11% at 400nm, 9% at 600nm) than the drug resistant variant MOR-R.
VPL pretreatment of the drug resistant large cell carcinoma line COR-L23-R resulted in a small increase in Ho342-DNA fluorescence at all time intervals after fluorochrome treatment (Figure 6a ), but this was also detectable in the parent line COR-L23, suggesting that the VPL modification of intracellular availability of the dye was not a function of the resistance phenotype in these cells. In contrast neither adeno-carcinoma line, MOR and MOR-R, showed a significant change in Ho342 fluorescence patterns following VPL pretreatment (Figure 6b ), suggesting that intracellular cytotoxic drug avilability is not a VPL sensitive process in either of these cell lines.
Discussion
We have described the use of spectral shift analysis of Ho342-DNA fluorescence for monitoring the classical MDR phenotype in lung cancer cells. LX4, a SCLC cell line in which exposure to ADM produced MDR, showed a reduced uptake of Ho342 when compared to the parent line, H69/P. In contrast only small differences were observed in Ho342-DNA fluorescence in two non-SCLC lines, suggesting that the mode of drug resistance in these non-SCLC cells was not solely related to reduced intra-nuclear availability of cytotoxic drug.
The significant enhancement of Ho342 fluorescence on binding to DNA allows assessment of the cellular content of the agent at the putative site of action; potentially important differences in sub-cellular localisation of cytotoxic agents are not identified by other techniques of drug uptake analysis currently employed. Our technique does not identify specific mechanisms effecting the reduced nuclear concentration of fluorochrome in a given cell line, for example reduced DNAfluorochrome binding by chromatin modification, or an active efflux mechanism at either cell, or nuclear, membrane sites. While assessment of whole cell uptake of ADM (Twentyman et al., 1986b) gave similar results in the SCLC cell lines as our method, showing a 50% reduction of ADM content in LX4 compared to H69/P, the results for non-SCLC cell lines were significantly diffeent, MOR-R showing a 90% reduction and COR/L23-R a 60% reduction in whole cell content of ADM compared to the parent cell line. Further investigation is required to ensure that this difference is not because of methodological variations.
The mechanism limiting fluorochrome access to DNA in LX4 was rapidly, but only partially, reversed by VPL, with a new equilibrium of dye-DNA fluorescence being reached after 20min, suggesting that the use of 30min pre-treatment with VPL was sufficient to produce maximal effect of the resistance modifier, at the concentration used, on the MDR mechanism in these cells. The presence of two components of MDR, only one of which is VPL sensitive, has been postulated in other mammalian MDR cell lines (Warr et al., 1988) , although the kinetics of VPL activity on nuclear accessibility has not been demonstrated previously. A smaller and equal effect of VPL on the Ho342-DNA fluorescence of the drug resistant and parent large cell carcinoma lines suggests that the VPL-induced changes in Ho342-DNA fluorescence may be mediated by a mechanism unrelated to the resistance phenotype. Modification of ADM cytotoxicity by VPL (at 6.6 juM concentration) in these cell lines has been reported previously (Twentyman et al., 1986a) ; the resistance factor, as defined in Table I , was reduced 8-fold for LX4, consistent with the VPL effect on nuclear fluorescence shown by our technique. However, a 4-fold reduction in resistance factor to ADM of MOR-R, and 3-fold reduction of resistance factor of COR/L23-R were also described, which may indicate a further chemosensitivity-modifying activity of VPL other than by altered intra-nuclear drug accumulation, which we were unable to demonstrate in these non-SCLC cell lines. LX4 is known to show increased expression of mdr-I gene encoding P170 membrane glycoprotein, demonstrated by Western blot analysis using MoAb C219 and Northern blot analysis using cDNA probe pHDR105 (Reeve et al., 1989) , and differs in this respect from both an ADM resistant variant of NCI-H69 developed elsewhere (Mirski et al., 1987) , and from COR/L23-R, neither of which MDR lines show enhanced P-glycoprotein levels (Reeve et al., 1988 (Loken, 1980) can also be used to identify cell subsets. Although there was no evidence within these cell lines of sub-populations of cells with respect to drug uptake, the rapidity of FCM should allow detection of even very low frequency events, such as spontaneously occurring mutant cells showing reduced drug uptake (Ross et al., 1988) . It has been postulated that within a heterogeneous population of human tumour cells even small differences in cytotoxic drug uptake, such as can be demonstrated by this technique, may produce significant differences in clinical responsiveness to cytotoxic drugs in vivo.
The cell of origin of SCLC is thought to differ from that of non-SCLC, and the diseases are also distinguished by clinical features including chemotherapeutic responsiveness. Expression of the mdr gene is known to differ in normal tissues from different sites (Fojo et al., 1987) , perhaps reflecting variation in tissue requirements for excretion of toxic substances (Arly Nelson, 1988) ; a differential effect of a cytotoxic agent producing the MDR phenotype, but with changes in mdr-l expression and Ho342 accumulation according to cell type, is not then unexpected, but the association observed in these lung cancer cell lines requires further investigation. The generation of two MDR variants from the same cell line (NCI-H69), showing similar degrees of chemo-resistance but one showing mdr-I gene amplification and expression (J.G. Reeve et al., manuscript in preparation) and one not (Mirski, 1987) , indicates the potential for development of multiple mechanisms of drug resistance within a single cell type. The significance of the MDR mechanism, identified in vitro following prolonged exposure to a single cytotoxic agent, to clinical patterns of drug resistance developing in vivo after treatment with a number of chemotherapy agents, given simultaneously and intermittently, is uncertain; further study is required with samples obtained directly from human solid tumours, for which the technique described here appears to be particularly suitable.
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